Physicians' Academy for Cardiovascular Education
The ORION-5 trial, in which 56 patients with homozygous familial hypercholesterolemia (HoFH) were treated with inclisiran or placebo, did not meet its primary endpoint of LDL-c reduction at 150 days. The PCSK9 level did decrease in the inclisiran group.
AHA 2023 Andrew Bellinger talks about VERVE-101, a novel base editing medicine which makes a single base pair change in the PCSK9 gene to lower PCSK9 and LDL-c. He shares three important observations of the first-in-human study with VERVE-101 in patients with HeFH and ASCVD.
AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab.
AHA 2023 One dose of VERVE-101, a CRISPR base editing therapy that inactivates PCSK9, resulted in dose-dependent reductions of PCSK9 protein and LDL-c in 10 HeFH patients with ASCVD and uncontrolled hypercholesterolemia and was overall safe.
In a post-hoc analysis of the ODYSSEY OUTCOMES trial, alirocumab reduced MACE in post-ACS patients who were eligible for 3 to 5 years of follow-up compared with placebo.
Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.
“We are only now beginning to understand how CETP inhibition works in terms of protection against cardiovascular disease”, says John Kastelein. He explains what we have learned from genetic research and clinical trials with CETP inhibitors.
"Oral cholesterol-lowering therapies are the basis of cardiovascular disease prevention", says Lale Tokgözoğlu. In this video, she talks about oral therapies.
A prespecified substudy of the PACMAN-AMI trial showed 1 year of alirocumab, on top of rosuvastatin, resulted in regression of the angiographic diameter stenosis of non-obstructive coronary lesions in acute MI patients, compared with an increase with placebo.
According to the latest registries, the majority of high- and very high-risk patients do not achieve the 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.
ESC Congress 2023 Investigators of the phase 3 LIBerate-HeFH trial reported data on the efficacy and safety of the small PCSK9 binding protein lerodalcibep in patients with heterozygous FH (HeFH).
ESC Congress 2023 The ORION-8 trial, an open-label extension of ORION-3/9/10/11, demonstrated the efficacy, safety and tolerability of inclisiran in patients with high cardiovascular risk and elevated LDL-c.
